Mark Murcko, Ph.D. has directly contributed to seven marketed drugs. He is a Founder, Board member, and was the interim CSO at Relay Therapeutics. In addition, Mark is a senior lecturer in the Department of Biological Engineering at MIT, and has served on numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations.
Mark was chief technology officer and chair of the SAB of Vertex Pharmaceuticals and was responsible for the identification, validation and implementation of disruptive technologies across R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He also led the early stages of Vertex's influenza program which lead to pimodivir, currently in Phase 3 trials.
Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover multiple clinical candidates, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, dorzolamide, was commercialized in two products, Trusopt and Cosopt. Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program.
He chaired the 2013 Gordon Research Conference in Medicinal Chemistry and is currently a member of the Board of Trustees of the GRC. He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles. Mark holds a Ph.D. in organic chemistry from Yale University.